Weekly Update: October 22 to November 3, 2022.
| Al Kaabi N, medrxiv, 2022 |
Safety and immunogenicity of a broad-spectrum mosaic vaccine as a booster dose against SARS-CoV-2 Omicron and other circulating variants |
| Al Kaabi N, Nat Commun, 2022 |
Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients: a randomized controlled phase 2 trial |
| Anderson E, Research Square, 2022 |
Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine An Interim Analysis |
| Anez G, medrxiv, 2022 |
Safety, Immunogenicity and Efficacy of NVX-CoV2373 in Adolescents in PREVENT-19: a Randomized, Phase 3 Trial |
| Bánki Z, EBioMedicine, 2022 |
Heterologous ChAdOx1/BNT162b2 vaccination induces stronger immune response than homologous ChAdOx1 vaccination: The pragmatic, multi-center, three-arm, partially randomized HEVACC trial. |
| Chen CJ, Nat Commun, 2022 |
A randomized controlled trial of heterologous ChAdOx1 nCoV-19 and recombinant subunit vaccine MVC-COV1901 against COVID-19 |
| Corominas J, medRxiv, 2022 |
Safety and immunogenicity of the protein-based PHH-IV compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial. |
| Fadlyana E, SSRN, 2022 |
Immunogenicity and Safety in Healthy Adults of Full-Dose Versus Half Doses of COVID-19 Vaccine (ChAdOx1-S or BNT162b2) or Full-Dose CoronaVac Administered as a Booster Dose after Priming with Coronavac: A Randomized, Observer-Blinded, Contr |
| Huang LM, Research Square, 2022 |
Safety and immunogenicity of SARS-CoV-2 vaccine MVC-COV1901 in Taiwanese adolescents: A double-blind, randomized, placebo-controlled phase 2 trial |
| Kulkarni PS, SSRN, 2022 |
Safety and Immunogenicity of SII-NVX-CoV2373 (COVID-19 Vaccine) In Adults in a Phase 2/3, Observer-Blind, Randomised, Controlled Study |
| Kundro MA, Public Health Pract (Oxf), 2022 |
Safety and immunogenicity of heterologous COVID-19 vaccine regimens to deal with product shortage: a randomised clinical trial in an elderly population |
| LAUNAY O, medrxiv, 2022 |
Immunogenicity and Safety of Beta Adjuvanted Recombinant Booster Vaccine |
| Leung N H L, medrxiv, 2022 |
Homologous and heterologous boosting with CoronaVac and BNT162b2: a randomized trial (the Cobovax study) |
| Lien CE, SSRN, 2022 |
A Phase I, Prospective, Randomized, Open-Labeled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Booster Dose with MVC-COV1901 or MVC-COV1901(Beta) SARS-CoV-2 Vaccine in Adults |
| Madhi, Lancet HIV, 2022 |
Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial |
| Mrak D, Nat Commun, 2022 |
Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial. |
| Niyomnaitham S, Hum Vaccin Immunother, 2022 |
Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adul |
| Puthanakit T; Vaccine: X; 2022 |
Heterologous Prime-boost of SARS-CoV-2 Inactivated Vaccine and mRNA BNT162b2 among Healthy Thai Adolescents. |
| Rose W, SSRN, 2022 |
Immunogenicity and Safety of Homologous and Heterologous Booster Vaccination of ChAdOx1 nCoV-19 (COVISHIELDTM) and BBV152 (COVAXIN®) in Previous Recipients of COVISHIELDTM or COVAXIN®: A Phase 4, Participant and Observer Blinded, Randomis |
| Sung JC, Vaccines, 2022 |
Safety and Immunogenicity of Inactivated Bacillus subtilis Spores as a Heterologous Antibody Booster for COVID-19 Vaccines. |
| Tabarsi P, Clin Microbiol Infect, 2022 |
Evaluating the Efficacy and Safety of SpikoGen®, an Advax-CpG55.2-adjuvanted SARS-CoV-2 Spike Protein Vaccine: a Phase 3 Randomized Placebo-Controlled Trial |
| Tabarsi P, CMI, 2022 |
Safety and immunogenicity of SpikoGen®, an advax-cpg55.2-adjuvanted sars-cov-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations. |
| Tabarsi P, Immunology, 2022 |
Immunogenicity and Safety of SpikoGen®, an Adjuvanted Recombinant SARS-CoV-2 Spike Protein vaccine as a Homologous and Heterologous Booster Vaccination: A Randomized Placebo-Controlled Trial. |
| Zhang Y, EClinicalMedicine, 2022 |
Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: a randomised, double-blinded, placebo-controlled, phase 2 trial |
37 early phase vaccine trials where the vaccine dose and schedule have not yet been determined :
| Abarca K, Vaccines, 2022 |
Safety and efficacy of two immunization schedules with an inactivated SARS-CoV-2 vaccine in adults. A randomized non-inferiority clinical trial. |
| Angkasekwinai N, Vaccine, 2021 |
Comparison of safety and immunogenicity of CoronaVac and ChAdOx1 against the SARS-CoV-2 circulating variants of concern (Alpha, Delta, Beta) in Thai healthcare workers |
| Butta N, SSRN, 2022 |
Effect of a COVID-19-Heterologous Vaccination Schedule on Haemostasis: A Subanalysis of the Phase 2, Multicentre, Randomised, Controlled CombiVacS Study |
| Cao Y, Sci China Life Sci, 2022 |
A third high dose of inactivated COVID-19 vaccine induces higher neutralizing antibodies in humans against the Delta and Omicron variants: a Randomized, Double-Blinded Clinical Trial. |
| Chen GL, Lancet microbe, 2022 |
Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial |
| Chen J, 2021 |
[A randomized controlled trial study of immunogenicity and safety of an inactivated SARS-CoV-2 vaccine in different immunization schedules]. |
| Chiuppesi F, Lancet Microbe, 2022 |
Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial. |
| Duc Dang A, Vaccine, 2022 |
Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam. |
| Follmann D, Ann Intern Med, 2022 |
Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial. |
| Garcia-Perez J, eClinicalMedicine, 2022 |
Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study. |
| Iwata S, Vaccine, 2022 |
Phase 1/2 Clinical Trial of COVID-19 Vaccine in Japanese Participants: A Report of Interim Findings |
| Jin P, PLoS med, 2022 |
Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial. |
| Launay O, EBioMedicine, 2022 |
Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study. |
| Leal L, medrxiv, 2022 |
Safety and Immunogenicity of a Recombinant Protein RBD Fusion Heterodimer Vaccine against SARS-CoV-2: preliminary results of a phase 1-2a dose-escalating, randomized, double-blind clinical trial |
| Lin KY, J Formos Med Assoc, 2022 |
Serological response after COVID-19 mRNA-1273 booster dose in immunocompromised patients, Taiwan, July to August 2021. |
| Luo D, Clin Transl Med, 2022 |
A randomized, double-blind, placebo-controlled phase 1 and phase 2 clinical trial to evaluate efficacy and safety of a SARS-CoV-2 vaccine SCoK in adults. |
| Marchevsky NG, eBioMedicine, 2022 |
An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females. |
| Mohraz M, BMJ Open, 2022 |
Safety and immunogenicity of an inactivated virus particle vaccine for SARS-CoV-2, BIV1-CovIran: findings from double-blind, randomised, placebo-controlled, phase I and II clinical trials among healthy adults. |
| NCT04569786 |
Dose Ranging Trial to Assess Safety and Immunogenicity of V590 in Healthy Adults (V590-001) |
| Orozco MN, medrxiv, 2022 |
Phase I study of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B |
| Ozdarendeli A, SSRN, 2022 |
Safety and Immunogenicity of an Inactivated Whole Virion SARS-CoV-2 Vaccine, TURKOVAC, in Healthy Adults: Interim Results from Randomised, Double-Blind, Placebo-Controlled Phase 1 and 2 Trials |
| Pajon R, Nat Med, 2022 |
Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial. |
| Pitisuttithum P, EClinicalMedicine, 2022 |
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial. |
| Pollock KM, eclinicalmedicine, 2022 |
Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial |
| Puthanakit T, vaccines, 2022 |
Immunogenicity of a Fractional Dose of mRNA BNT162b2 COVID-19 Vaccine for Primary Series and Booster Vaccination among Healthy Adolescents. |
| Robbins JA, eBioMedicine, 2022 |
Safety and immunogenicity of intramuscular, single-dose V590 (rVSV-SARS-CoV-2 Vaccine) in healthy adults: Results from a phase 1 randomised, double-blind, placebo-controlled, dose-ranging trial. |
| Saez-Llorens X , SSRN, 2021 |
Safety and Immunogenicity of mRNA-LNP COVID-19 Vaccine CVnCoV in Latin American Adults; A Phase 2 Randomized Study |
| Song JY, EClinicalMedicine, 2022 |
Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial. |
| Tanishima M, medRxiv, 2022 |
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, KD-414, in healthy adult and elderly subjects: a randomized, double-blind, placebo-controlled, phase 1/2 clinical study in Japan |
| Thuluva S, EBioMedicine, 2022 |
Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials |
| Thuluva S, medRxiv, 2022 |
Selection of optimum formulation of RBD-based protein sub-unit covid19 vaccine (Corbevax) based on safety and immunogenicity in an open-label, randomized Phase-1 and 2 clinical studies |
| Vanhoutte F, EBioMedicine, 2022 |
Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1/2 randomised, double-blind, placebo-controlled, dose-ranging trial |
| Waits A, Int J Infect Dis, 2022 |
Safety and Immunogenicity of MVC-COV1901 Vaccine in Older Adults: phase 2 Randomized Dose-Comparison Trial |
| Wang CY, J Clin Invest, 2022 |
A multitope SARS-COV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants. |
| Wynne C, medRxiv, 2022 |
The preliminary safety and immunogenicity results of a randomized, double-blind, placebo-controlled Phase I trial for a recombinant two-component subunit SARS-CoV-2 vaccine ReCOV |
| Xia S, Front Immunol, 2022 |
Safety and Immunogenicity of an Inactivated COVID-19 Vaccine, WIBP-CorV, in Healthy Children: Interim Analysis of a Randomized, Double-Blind, Controlled, Phase 1/2 Trial. |
| Zhu, Lancet Respir Med., 2022 |
Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials |